Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. Company
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Knight Therapeutics Inc.
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. It owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.

Number of employees : 973 people.
Sales per Business
2020
Pharmaceutical Products, Consumer Health Products and Medical Devices199.52100%
CAD in Million
Sales per region
20192020Delta
Brazil22.9648.4%78.7139.4% +242.78%
Argentina3.196.7%37.8519% +1085.68%
Colombia4.359.2%34.8217.5% +699.84%
Rest of Latin America3.417.2%33.8617% +891.89%
Other11.1723.5%9.294.7% -16.83%
Canada2.375%5.002.5% +110.67%
CAD in Million
Managers
Name Title Age Since
Samira Sakhia President, Chief Executive Officer & Director 51 2021
Utchanah Arvind Chief Financial Officer - 2020
James Charles Gale Lead Independent Director 70 2021
Robert N. Lande Independent Director 57 2014
Michael Tremblay Independent Director - 2019
Amal Khouri Vice President-Business Development - 2014
Members of the board
Name Title Age Since
Jonathan Ross Goodman Executive Chairman 52 2021
James Charles Gale Lead Independent Director 70 2021
Robert N. Lande Independent Director 57 2014
Samira Sakhia President, Chief Executive Officer & Director 51 2021
Michael Tremblay Independent Director - 2019
Nicolás Sujoy Spiguel Director - -
Janice Murray Director - -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 122,241,870 102,091,381 83.5% 0 0.0% 83.5%
Shareholders
NameEquities%
Long Zone Holdings, Inc. 21,667,133 17.6%
Resolute Funds Ltd. 12,500,000 10.2%
Edgepoint Investment Group, Inc. 7,268,559 5.90%
Mawer Investment Management Ltd. 3,722,505 3.02%
QV Investors, Inc. 3,203,950 2.60%
Dimensional Fund Advisors LP 2,352,698 1.91%
Janus Capital Management LLC 1,775,357 1.44%
Fidelity Investments Canada ULC 1,106,193 0.90%
Invesco Capital Management LLC 1,047,625 0.85%
Van Berkom & Associates, Inc. 808,709 0.66%
Company contact information
Knight Therapeutics, Inc.
3400 de Maisonneuve West
Suite 1055
Montréal, QC H3Z 3B8

Phone : +1.514.484.4483
Fax : +1.514.481.4116
Web : http://www.gud-knight.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Knight Therapeutics Inc.